MEPIRAPIM
From Wikipedia, the free encyclopedia
 |
|
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
|
|
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C19H27N3O |
| Molar mass | 313.45 g·mol−1 |
| 3D model (Jmol) | |
|
|
|
|
MEPIRAPIM is a indole-based cannabinoid which differs from JWH-018 by having a 4-methylpiperazine group in place of the naphthyl group[1] and has been used as an active ingredient in synthetic cannabis products. It was first identified in Japan in 2013, alongside FUBIMINA.[2]
Legality[edit]
Sweden's public health agency suggested to classify MEPIRAPIM as hazardous substance on November 10, 2014.[3]
See also[edit]
References[edit]
- ^ "MEPIRAPIM". Cayman Chemical. Retrieved 23 June 2015.
- ^ Uchiyama N, Shimokawa Y, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (January 2014). "Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products". Forensic Toxicology. 32 (1): 105–115. doi:10.1007/s11419-013-0217-2.
- ^ "Cannabinoider föreslås bli klassade som hälsofarlig vara". Retrieved 29 June 2015.
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
